Inhibrx Biosciences, Inc. (INBX): Entry into a Material Definitive Agreement
Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 oxfordinhibrx-secondamendm.htm EX-10.1 Document Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “ Amendment ”) is entered into as of July 15, 2026, by and among OXFORD FINANCE LLC, a Delaware limite
How this was made
The 30-second read
Why it matters
The amendment restates loan availability terms by tranche and requires a pledge agreement covering equity securities Inhibrx holds in Poplar Therapeutics, increasing secured creditor protection.
Market read
Traders may reassess INBX’s near-term liquidity and leverage profile based on the expanded secured term-loan availability and the new collateral pledge.
What to watch
Equity reaction will depend on (not provided here) interest rate, maturity, repayment schedule, and any new or tightened covenants tied to the pledged Poplar Therapeutics stake.
Background
The 8-K reports entry into a material definitive agreement via a Second Amendment to an existing Loan and Security Agreement dated January 13, 2025.
Ticker impact
Inhibrx entered a Second Amendment to its Loan and Security Agreement, expanding term-loan availability and adding Poplar Therapeutics equity as pledged collateral.
Likely modest positive bias on liquidity optics, with downside risk if investors focus on leverage/collateral overhang.
The 8-K is a primary-source debt amendment with specific incremental loan tranches ($100M, $75M, $100M, plus potential $225M Term D), but the excerpt does not disclose pricing, covenants, or draw timing, limiting precision on equity impact.
Market effects
For biotech lenders and small-cap biotech credit, the amendment highlights continued appetite for secured, collateral-backed financing structures.
No clear regional spillover beyond US small-cap biotech credit markets.
Limited global relevance; this is company-specific secured debt documentation.
Counterpoint
The incremental facility may be viewed as a sign the company needs additional secured capital, which can cap upside and pressure equity if future draws are likely.
Key entities
- issuerInhibrx Biosciences, Inc.
Borrower that entered the Second Amendment to its Loan and Security Agreement.
- lender_collateral_agentOxford Finance LLC
Collateral agent for the lenders under the amended loan agreement.
- collateral_targetPoplar Therapeutics
Equity securities held by Inhibrx are pledged as collateral under the contemporaneous pledge agreement.
